AbbVie said the impairment charge is related to last year’s $8.7 billion bet on Cerevel following the failure of the deal’s ...

AbbVie said it would take a $3.5 billion dollar impairment charge related to the failure of a drug it acquired in its purchase of Cerevel Therapeutics. The biotech company reported in November ...

In a regulatory filing, AbbVie (ABBV) stated, “On January 9, 2025, AbbVie determined that it will record an impairment charge related to the ...

The schizophrenia drug Emraclidine failed to perform in clinical trials but executives say it can still “play a role.” ...

The drugmaker acquired the experimental drug emraclidine, with its $8.7 billion purchase of Cerevel Therapeutics, gaining a portfolio of drugs being tested for a range of neurological conditions.

an experimental medicine to treat schizophrenia in adults that AbbVie acquired when it purchased Cerevel Therapeutics Holdings. AbbVie reported in November that a Phase 2 trial of emraclidine ...

AbbVie (NYSE:ABBV) said it expects to record an impairment charge of approximately $3.5B related to the drug emraclidine, ...

The firm has bought neuroscience drug developer Cerevel Therapeutics, cancer drug developer ImmunoGen and Alzheimer's therapy developer Aliada in 2024 through deals worth over $20 billion in total.

By Sneha S K and Christy Santhosh (Reuters) -AbbVie plans to "commit less capital" towards experimental medicines for ...

AbbVie added emraclidine via the approximately $8.7 billion acquisition of Cerevel Therapeutics. Price Action: JNJ stock is up 0.86% at $143.28, and ITCI stock is up 34.5% at $127.62 at the last ...

Rein Therapeutics (RNTX), formerly known as Aileron Therapeutics (ALRN), has changed its name to Rein Therapeutics. The new name, logo, website, and branding elements reflect the Company’s ...